Lesson plan

Erythromer

ErythroMer is a red blood cell substitute in development by KaloCyte, supported with funding by the National Institutes of Health, U.S. Department of Defense, and private investment. Similar to other hemoglobin-based oxygen carriers, the product is stable for several months even when freeze-dried. It can be reconstituted from this lyophilized state in emergencies. This opens up the possibility of eventual stockpiling of ErythroMer, making it easier to supply blood in large amounts to those who need it. The development of this technology was done at Washington University in St. Louis and University of Illinois Urbana-Champaign. Trials have been successful in rats, mice, and rabbits, and human trials are planned. ErythroMer is a reddish blood powder composed of hemoglobin from humans. By coating it with a synthetic polymer, it can sense pH changes, allowing for oxygen pick up in areas where the pH levels are high and disposal where they are low. In the spring of 2024, ErythroMer showed promise in pre-clinical testing. In animal testing, it effectively delivered oxygen and helped revive animals with significant blood loss. In 2025, KaloCyte announced a licensing agreement with Chrysea for ErythroMer production.

Back to article

Article summary

ErythroMer is a red blood cell substitute in development by KaloCyte, supported with funding by the National Institutes of Health, U.S. Department of Defense, and private investment. Similar to other hemoglobin-based oxygen carriers, the product is stable for several months even when freeze-dried. It can be reconstituted from this lyophilized state in emergencies. This opens up the possibility of eventual stockpiling of ErythroMer, making it easier to supply blood in large amounts to those who need it. The development of this technology was done at Washington University in St. Louis and University of Illinois Urbana-Champaign. Trials have been successful in rats, mice, and rabbits, and human trials are planned. ErythroMer is a reddish blood powder composed of hemoglobin from humans. By coating it with a synthetic polymer, it can sense pH changes, allowing for oxygen pick up in areas where the pH levels are high and disposal where they are low. In the spring of 2024, ErythroMer showed promise in pre-clinical testing. In animal testing, it effectively delivered oxygen and helped revive animals with significant blood loss. In 2025, KaloCyte announced a licensing agreement with Chrysea for ErythroMer production.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.